Literature DB >> 21729801

Adjacent vertebral body osteolysis with bone morphogenetic protein use in transforaminal lumbar interbody fusion.

Melvin D Helgeson1, Ronald A Lehman, Jeanne C Patzkowski, Anton E Dmitriev, Michael K Rosner, Andrew W Mack.   

Abstract

BACKGROUND CONTEXT: Recent studies have demonstrated cases of adjacent vertebral body osteolysis when assessing the effect of bone morphogenetic protein (BMP) on fusion rates. However, no study to date has evaluated the course of osteolysis at different periods.
PURPOSE: To determine the incidence and resolution of osteolysis associated with BMP used in transforaminal lumbar interbody fusions (TLIF). STUDY
DESIGN: Retrospective review. PATIENT SAMPLE: All TLIF cases using BMP performed at one institution with routine postoperative computed tomography (CT) scans at defined intervals. OUTCOME MEASURES: Area of osteolysis and fusion as determined by CT scan.
METHODS: We performed a retrospective analysis of all patients at our facility who underwent TLIF with BMP. Included were all patients who had obtained a CT scan within 48 hours of surgery, 3 to 6 months postoperatively, and 1 to 2 years postoperatively. Areas of osteolysis were defined as lucency within the vertebral body communicating with the interbody spacer that was not present on the immediately postoperative CT scan. Areas of osteolysis were measured in all three planes and the volume used for comparison of the 3 to 6 months CT scans with the greater than 1 year CT scan.
RESULTS: Twenty-three patients who underwent TLIF with BMP had obtained CT scans at all time periods required for evaluation. Seventy-eight vertebral bodies/end plates were assessed for osteolysis (39 levels). The incidence of osteolysis 3 to 6 months postoperatively in the adjacent vertebral bodies was 54% compared with 41% at 1 to 2 years. The mean volume of osteolysis was at 0.216 cm(3) at 1 to 2 years compared with 0.306 cm(3) at 3 to 6 months (p=.082). The area/rate of osteolysis did not appear to significantly affect the rate of fusion or final outcome with an overall union rate of 83%.
CONCLUSIONS: The rate of osteolysis decreased at 1 year compared with 3 to 6 months, but only 24% of the vertebral bodies with evidence of osteolysis at 3 to 6 months completely resolved by 1 year. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21729801     DOI: 10.1016/j.spinee.2011.01.017

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  14 in total

1.  Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect.

Authors:  Sofia Bougioukli; Ashish Jain; Osamu Sugiyama; Brian A Tinsley; Amy H Tang; Matthew H Tan; Douglas J Adams; Paul J Kostenuik; Jay R Lieberman
Journal:  Bone       Date:  2015-12-23       Impact factor: 4.398

2.  Bone morphogenetic protein and orthopaedic surgery: can we legitimate its off-label use?

Authors:  Aurélien Courvoisier; Frederic Sailhan; Olivier Laffenêtre; Laurent Obert
Journal:  Int Orthop       Date:  2014-09-30       Impact factor: 3.075

Review 3.  Gene therapy approaches to regenerating bone.

Authors:  Nadav Kimelman Bleich; Ilan Kallai; Jay R Lieberman; Edward M Schwarz; Gadi Pelled; Dan Gazit
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

4.  Cyst-Like Osteolytic Formations in Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) Augmented Sheep Spinal Fusion.

Authors:  Hsin Chuan Pan; Soonchul Lee; Kang Ting; Jia Shen; Chenchao Wang; Alan Nguyen; Emily A Berthiaume; Janette N Zara; A Simon Turner; Howard B Seim; Jin Hee Kwak; Xinli Zhang; Chia Soo
Journal:  Am J Pathol       Date:  2017-05-11       Impact factor: 4.307

Review 5.  A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2.

Authors:  Aaron W James; Gregory LaChaud; Jia Shen; Greg Asatrian; Vi Nguyen; Xinli Zhang; Kang Ting; Chia Soo
Journal:  Tissue Eng Part B Rev       Date:  2016-04-19       Impact factor: 6.389

6.  Vertebral body fracture following stand-alone lateral lumbar interbody fusion (LLIF): report of two events out of 712 levels.

Authors:  Zachary J Tempel; Gurpreet S Gandhoke; Bryan D Bolinger; David O Okonkwo; Adam S Kanter
Journal:  Eur Spine J       Date:  2015-03-17       Impact factor: 3.134

Review 7.  Recommendations and considerations for the use of biologics in orthopedic surgery.

Authors:  Stefan Zwingenberger; Christophe Nich; Roberto D Valladares; Zhenyu Yao; Maik Stiehler; Stuart B Goodman
Journal:  BioDrugs       Date:  2012-08-01       Impact factor: 5.807

8.  Comparison of fusion rates following transforaminal lumbar interbody fusion using polyetheretherketone cages or titanium cages with transpedicular instrumentation.

Authors:  Osamu Nemoto; Takashi Asazuma; Yoshiyuki Yato; Hideaki Imabayashi; Hiroki Yasuoka; Akira Fujikawa
Journal:  Eur Spine J       Date:  2014-07-12       Impact factor: 3.134

9.  Forces associated with launch into space do not impact bone fracture healing.

Authors:  Paul Childress; Alexander Brinker; Cynthia-May S Gong; Jonathan Harris; David J Olivos; Jeffrey D Rytlewski; David C Scofield; Sungshin Y Choi; Yasaman Shirazi-Fard; Todd O McKinley; Tien-Min G Chu; Carolynn L Conley; Nabarun Chakraborty; Rasha Hammamieh; Melissa A Kacena
Journal:  Life Sci Space Res (Amst)       Date:  2017-11-11

10.  Transforaminal lumbar interbody fusion and posterior lumbar interbody fusion utilizing BMP-2 in treatment of degenerative spondylolisthesis: neither safe nor cost effective.

Authors:  Bradley Moatz; P Justin Tortolani
Journal:  Surg Neurol Int       Date:  2013-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.